Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways

Lignende værker

• Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway
  af: Chen, Dongshao, et al.
  Udgivet: (2018)
• CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest
  af: Wang, Jiayuan, et al.
  Udgivet: (2017)
• A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo
  af: Zou, Jianling, et al.
  Udgivet: (2018)
• Targeting autophagy potentiates antitumor activity of Met-TKIs against Met-amplified gastric cancer
  af: Lin, Xiaoting, et al.
  Udgivet: (2019)
• Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint
  af: Lin, Xiaoting, et al.
  Udgivet: (2018)